Merit Medical Systems (NASDAQ:MMSI – Get Rating) and DarioHealth (NASDAQ:DRIO – Get Rating) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations and dividends.
Valuation & Earnings
This table compares Merit Medical Systems and DarioHealth’s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Merit Medical Systems | $1.15 billion | 3.46 | $74.52 million | $1.30 | 53.51 |
| DarioHealth | $27.66 million | 3.77 | -$62.19 million | ($2.63) | -1.53 |
Merit Medical Systems has higher revenue and earnings than DarioHealth. DarioHealth is trading at a lower price-to-earnings ratio than Merit Medical Systems, indicating that it is currently the more affordable of the two stocks.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Merit Medical Systems | 0 | 1 | 5 | 0 | 2.83 |
| DarioHealth | 0 | 0 | 4 | 0 | 3.00 |
Merit Medical Systems presently has a consensus target price of $76.33, indicating a potential upside of 9.74%. DarioHealth has a consensus target price of $12.63, indicating a potential upside of 213.28%. Given DarioHealth’s stronger consensus rating and higher probable upside, analysts plainly believe DarioHealth is more favorable than Merit Medical Systems.
Profitability
This table compares Merit Medical Systems and DarioHealth’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Merit Medical Systems | 6.47% | 14.28% | 9.50% |
| DarioHealth | -224.88% | -64.99% | -48.76% |
Institutional and Insider Ownership
95.4% of Merit Medical Systems shares are owned by institutional investors. Comparatively, 35.8% of DarioHealth shares are owned by institutional investors. 3.8% of Merit Medical Systems shares are owned by company insiders. Comparatively, 9.4% of DarioHealth shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Volatility & Risk
Merit Medical Systems has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Comparatively, DarioHealth has a beta of 1.34, suggesting that its share price is 34% more volatile than the S&P 500.
Summary
Merit Medical Systems beats DarioHealth on 8 of the 13 factors compared between the two stocks.
About Merit Medical Systems
Merit Medical Systems, Inc. engages in the manufacture and marketing of proprietary disposable medical devices. It operates through the Cardiovascular and Endoscopy segments. The Cardiovascular segment consists of peripheral intervention, cardiac intervention, interventional oncology and spine, and cardiovascular and critical care product groups. The Endoscopy segment integrates non-vascular stent technology with balloon dilators, inflation devices, guide wires, procedure kits, and other devices that are used by gastroenterologists, endoscopists, pulmonologists, and thoracic and general surgeons. The company was founded by Fred P. Lampropoulos, Darla Gill, Kent W. Stanger, and William Padilla in July 1987 and is headquartered in South Jordan, UT.
About DarioHealth
DarioHealth Corp. is a digital therapeutics company, which engages in the research, development, and sale of pharmaceutical products. It offers a monitoring device, mobile application, and data services for diabetes management. The firm solutions include MyDario, Daro Engage, and Dario Intelligence. The company was founded by Oren Fuerst, Shoshana Friedman, David Weintraub, Dov Oppenheim, and Shilo Ben Zeev on August 11, 2011 and is headquartered in New York, NY.
Receive News & Ratings for Merit Medical Systems Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merit Medical Systems and related companies with MarketBeat.com's FREE daily email newsletter.
